Hansoh Pharmaceutical Group Company Limited Hansoh Pharmaceutical Group Company Limited

Hansoh Pharmaceutical Group Company Limited

3692

Kedudukan dalam Saham #970
Hansoh Pharmaceutical Group Company Limited, an investment holding company,... Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Fulairui, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product; and with Merck Sharp & Dohme LLC (MSD) to develop, manufacture, and commercialize HS-10535, an investigational pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The company was founded in 1995 and is headquartered in Shanghai, China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.
Harga Saham
$4.06
Disegerakkan terakhir: 2026-10-16
Modal Pasaran
$24.62B
Perubahan (1 hari)
1.15%
Perubahan (1 tahun)
-13.40%
Negara
CN
Perdagangan Hansoh Pharmaceutical Group Company Limited (3692)

Kategori

Healthcare
Sejarah dividen untuk Hansoh Pharmaceutical Group Company Limited (3692)
Hansoh Pharmaceutical Group Company Limited (simbol saham: 3692) telah membuat sejumlah 8 pembayaran dividen.
Jumlah semua dividen (disesuaikan untuk pemecahan saham): $1.00
Hasil dividen (TTM): 0.0154
Pembayaran dividen untuk Hansoh Pharmaceutical Group Company Limited (3692) dari 2021 hingga 2026
Pembayaran dividen tahunan
Tahun Dividen (diselaraskan untuk pemecahan saham) Ubah
2026 (TTM) $0.2316 -36.88%
2025 $0.3669 6.91%
2024 $0.3432 184.34%
2023 $0.1207 34.11%
2022 $0.09 16.73%
2021 $0.0771 0.00%
Senarai semua pembayaran dividen
Tahun Dividen Ubah
2026 (TTM) $0.2316 -36.88%
2025 $0.3669 6.91%
2024 $0.3432 184.34%
2023 $0.1207 34.11%
2022 $0.09 16.73%
2021 $0.0771 0.00%
Pembayaran dividen untuk syarikat serupa atau pesaing